SCHEMBL14720338

SCHEMBL14720338

Oc1ccc2ccc(Cl)cc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.50
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
DYRK1A Q13627 2/20 0.40
F7 P08709 1/20 0.40
F3 P13726 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
PIK3CG P48736 1/20 0.39
HSD17B10 Q99714 4/20 0.39
ALDH1A1 P00352 3/20 0.39
TSHR P16473 2/20 0.39
CYP3A4 P08684 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP2A6 P11509 1/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL934918 0.84 HTR3A (0.45) NR4A2HTR3ADYRK1AF7F3
SCHEMBL2133059 0.76 NR4A2 (0.54) NR4A2HTR3EHTR3BHTR3AHTR3D
SCHEMBL5958458 0.76 ALDH1A1 (0.54) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL30506415 0.76 NR4A2 (0.54) NR4A2HTR3EHTR3BHTR3AHTR3D
SCHEMBL7608692 0.75 NR4A2 (0.52) NR4A2HTR3EHTR3BHTR3AHTR3D
SCHEMBL1574290 0.74 PIK3CG (0.46) NR4A2DYRK1AF7F3HRH3
SCHEMBL25321171 0.73 CYP1A2 (0.35) ALDH1A1MEN1KMT2ACYP1A2
SCHEMBL5833376 0.73 NR4A2 (0.50) NR4A2HTR3EHTR3BHTR3AHTR3D
SCHEMBL462171 0.73 BACE1 (0.58) NR4A2PIK3CGMAPTALOX15MAPK1
SCHEMBL5542408 0.73 CYP1A2 (0.61) HSD17B10ALDH1A1TDP1CYP2A6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210346367-A1 O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-11-11 US disclosed
CN-111362872-A Synthetic method of 4, 7-dichloroquinoline 重庆医药高等专科学校 2020-07-03 CN disclosed
WO-2020047251-A1 O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-03-05 WO disclosed
EP-2744333-B1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-10-05 EP disclosed
US-9084794-B2 Fatty acid synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2015-07-21 US disclosed
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property (No2) Limite (GB) 2014-07-10 US disclosed
EP-2744333-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-06-25 EP disclosed
WO-2013028447-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS2, FADS1 NR4A2 2779/4885HTR3E 3841/4885HTR3B 3087/4885
US-20210346367-A1 O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF OGT, OGA, UGGT1 NR4A2 3093/4885HTR3E 3937/4885HTR3B 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.